<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Immuneering Corp — News on 6ix</title>
    <link>https://6ix.com/company/immuneering-corp</link>
    <description>Latest news and press releases for Immuneering Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/immuneering-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835839378dffbe2df0fcc09.webp</url>
      <title>Immuneering Corp</title>
      <link>https://6ix.com/company/immuneering-corp</link>
    </image>
    <item>
      <title>Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting</guid>
      <pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
      <description>- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation will highlight data from an expanded cohort totaling 55 first-line patients - NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that updated</description>
    </item>
    <item>
      <title>Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-and-beyond</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-and-beyond</guid>
      <pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
      <description>Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the genetic alterations most commonly associated with resistance to RAS inhibitors, providing molecular rationale to treat with atebimetinib early NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping</description>
    </item>
    <item>
      <title>Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-to-present-molecular-data-at-2026-aacr-annual-meeting-from-atebimetinib-treated-patients-highlighting-mechanism-designed-to-improve-durability-and-survival</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-to-present-molecular-data-at-2026-aacr-annual-meeting-from-atebimetinib-treated-patients-highlighting-mechanism-designed-to-improve-durability-and-survival</guid>
      <pubDate>Tue, 17 Mar 2026 20:35:00 GMT</pubDate>
      <description>NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms by which atebimetinib aims to improve overall survival: shrinking tumors durably. The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Inhi</description>
    </item>
    <item>
      <title>Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-19</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates-19</guid>
      <pubDate>Fri, 06 Mar 2026 12:45:00 GMT</pubDate>
      <description>- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 - - On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 - - Dosing in Phase 2 trial of atebimetin</description>
    </item>
    <item>
      <title>Immuneering to Present at the Leerink Global Healthcare Conference</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-to-present-at-the-leerink-global-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-to-present-at-the-leerink-global-healthcare-conference</guid>
      <pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
      <description>NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company’s pipeline, platform, and business strategy. Format: Fireside Chat and 1x1 Investor Meetings Date/Time</description>
    </item>
    <item>
      <title>Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
      <pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
      <description>NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company’s pipeline, platform,</description>
    </item>
    <item>
      <title>Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announces-exceptional-64-overall-210000584</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announces-exceptional-64-overall-210000584</guid>
      <pubDate>Wed, 07 Jan 2026 21:00:00 GMT</pubDate>
      <description>- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Com</description>
    </item>
    <item>
      <title>Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announce-12-month-overall-130000278</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announce-12-month-overall-130000278</guid>
      <pubDate>Tue, 23 Dec 2025 13:00:00 GMT</pubDate>
      <description>NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patie</description>
    </item>
    <item>
      <title>Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-advances-towards-dosing-first-210500690</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-advances-towards-dosing-first-210500690</guid>
      <pubDate>Wed, 17 Dec 2025 21:05:00 GMT</pubDate>
      <description>– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and h</description>
    </item>
    <item>
      <title>Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-added-nasdaq-biotechnology-index-130000182</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-added-nasdaq-biotechnology-index-130000182</guid>
      <pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
      <description>NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are</description>
    </item>
    <item>
      <title>Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-present-piper-sandler-37th-130000333</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-present-piper-sandler-37th-130000333</guid>
      <pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
      <description>NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chi</description>
    </item>
    <item>
      <title>Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-reports-third-quarter-2025-210500008</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-reports-third-quarter-2025-210500008</guid>
      <pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
      <description>- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer - - Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 - - New report</description>
    </item>
    <item>
      <title>Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-report-third-quarter-2025-210500143</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-report-third-quarter-2025-210500143</guid>
      <pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
      <description>- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financial results and trial investigators w</description>
    </item>
    <item>
      <title>Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-discuss-recently-announced-overall-200100965</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-discuss-recently-announced-overall-200100965</guid>
      <pubDate>Fri, 26 Sep 2025 20:01:00 GMT</pubDate>
      <description>NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in o</description>
    </item>
    <item>
      <title>Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announces-pricing-175-million-040800145</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announces-pricing-175-million-040800145</guid>
      <pubDate>Thu, 25 Sep 2025 04:08:00 GMT</pubDate>
      <description>NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering’s Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwr</description>
    </item>
    <item>
      <title>Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announces-proposed-underwritten-public-200500576</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announces-proposed-underwritten-public-200500576</guid>
      <pubDate>Wed, 24 Sep 2025 20:05:00 GMT</pubDate>
      <description>NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the “Offering”). In addition, Immuneering intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of Class A com</description>
    </item>
    <item>
      <title>Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announces-extraordinary-86-overall-200100258</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announces-extraordinary-86-overall-200100258</guid>
      <pubDate>Wed, 24 Sep 2025 20:01:00 GMT</pubDate>
      <description>- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company f</description>
    </item>
    <item>
      <title>Immuneering Appoints Dr. Thomas Schall as Chairman of the Board</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-appoints-dr-thomas-schall-110000789</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-appoints-dr-thomas-schall-110000789</guid>
      <pubDate>Tue, 16 Sep 2025 11:00:00 GMT</pubDate>
      <description>Thomas Schall Thomas Schall, Chariman of the Board of Directors of Immuneering NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder</description>
    </item>
    <item>
      <title>Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announce-updated-overall-survival-110000923</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announce-updated-overall-survival-110000923</guid>
      <pubDate>Wed, 10 Sep 2025 11:00:00 GMT</pubDate>
      <description>- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared</description>
    </item>
    <item>
      <title>Immuneering Announces Closing of $25 Million Private Placement</title>
      <link>https://6ix.com/company/immuneering-corp/news/immuneering-announces-closing-25-million-200500590</link>
      <guid isPermaLink="true">https://6ix.com/company/immuneering-corp/news/immuneering-announces-closing-25-million-200500590</guid>
      <pubDate>Tue, 26 Aug 2025 20:05:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The private placement was made to top-tier institutional and accredited investors, for total up front gross proceeds of approximately $25 million, before deducting fees and expenses. Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the</description>
    </item>
  </channel>
</rss>